Search - tctmd.com

Displaying 201 - 220 of 981

Sort: Relevancy | Date

DOACs May Up Post-TAVR Survival in A-fib: OCEAN-TAVI

News Daily News

DOACs May Up Post-TAVR Survival in A-fib: OCEAN-TAVI

October 29, 2020

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

News Daily News

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Michael O'Riordan

October 28, 2020

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

News Conference News TCT 2020

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

Michael O'Riordan

October 23, 2020

While Rare, Surgical Removal of TAVR Carries Risks: Global EXPLANT-TAVR Registry

News Conference News TCT 2020

While Rare, Surgical Removal of TAVR Carries Risks: Global EXPLANT-TAVR Registry

October 21, 2020

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

News Conference News TCT 2020

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

October 17, 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

News Conference News TCT 2020

MitraBridge: Could a MitraClip Help Patients Avoid Heart Transplant?

October 16, 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

News Conference News TCT 2020

Large Databases Hint at Sentinel Benefit During TAVR, but Uncertainty Remains

October 16, 2020

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Presentation TCT 2020

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Presenter: Jeffrey W. Moses

October 15, 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

News Conference News TCT 2020

Efficacy Eludes TriGUARD 3 Cerebral Protection Device: REFLECT II

October 15, 2020

PARTNER Data Back 5-Year Durability of Sapien 3 TAVR

News Daily News

PARTNER Data Back 5-Year Durability of Sapien 3 TAVR

October 12, 2020

TCTMD’s Top 10 Most Popular Stories for September 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

October 01, 2020

TAVR and Infective Endocarditis—Two Studies Address a Shifting Landscape

News Daily News

TAVR and Infective Endocarditis—Two Studies Address a Shifting Landscape

September 14, 2020

Which TAVR Device Is Best? Review Tackles Optimal Selection

News Daily News

Which TAVR Device Is Best? Review Tackles Optimal Selection

Michael O'Riordan

September 09, 2020

Unruptured Thoracic Aneurysm in TAVR Tied to Aortic Dissection, Cardiac Tamponade

News Daily News

Unruptured Thoracic Aneurysm in TAVR Tied to Aortic Dissection, Cardiac Tamponade

August 25, 2020

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

News Daily News

Should Guidelines Support TAVR for Low-Risk Patients? Two Views

August 17, 2020

Next-Day Discharge Safe After Uncomplicated Transfemoral TAVR

News Daily News

Next-Day Discharge Safe After Uncomplicated Transfemoral TAVR

August 12, 2020

August 2020 News Roundup

News Opinion CV Team Dispatch

August 2020 News Roundup

August 01, 2020

ViV TAVR Beats Redo SAVR for Short- but Not Long-term Outcomes

News Daily News

ViV TAVR Beats Redo SAVR for Short- but Not Long-term Outcomes

July 27, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.